OCREVUS ZUNOVO
OCREVUS ZUNOVO is a combination of ocrelizumab and hyaluronidase-ocsq indicated for the treatment of multiple sclerosis in adult patients. It is approved for relapsing forms of the disease, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The medication is also indicated for the treatment of primary progressive multiple sclerosis. This therapeutic provides a CD20-directed treatment option for various stages of the condition.
How OCREVUS ZUNOVO Works
Ocrelizumab is a cytolytic antibody that targets CD20, an antigen found on the surface of pre-B and mature B lymphocytes. Upon binding, it induces B cell depletion through antibody-dependent cellular cytolysis and complement-mediated lysis. The hyaluronidase component functions by depolymerizing hyaluronan to transiently increase the permeability of the subcutaneous tissue at the injection site. This local effect is reversible, with tissue permeability typically restored within 24 to 48 hours.
Details
- Status
- Prescription
- First Approved
- 2024-09-13
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
OCREVUS ZUNOVO Approval History
What OCREVUS ZUNOVO Treats
1 indicationsOCREVUS ZUNOVO is approved for 1 conditions since its original approval in 2024. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Multiple Sclerosis
OCREVUS ZUNOVO Target & Pathway
ProTarget
A protein found on the surface of B-cells but not stem cells or plasma cells. Anti-CD20 antibodies deplete B-cells, making them effective in B-cell cancers and autoimmune diseases where B-cells drive pathology.
OCREVUS ZUNOVO Competitors
Pro10 other drugs also target CD20. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (CD20). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to OCREVUS ZUNOVO
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
OCREVUS ZUNOVO FDA Label Details
ProIndications & Usage
FDA Label (PDF)OCREVUS ZUNOVO is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults OCREVUS ZUNOVO is a CD20-directed cytolytic antibody indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.